CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Detailed price information for Caribou Biosciences Inc (CRBU-Q) from The Globe and Mail including charting and trades.

ARK also continued its buying trend in CRISPR Therapeutics AG (NASDAQ:CRSP), acquiring 39,250 shares valued at $2,142,265. This purchase adds to the fund’s recent accumulation of CRISPR stock over the ...

CRISPR Therapeutics (CRSP) shares have seen notable movement over the past month, with the stock down about 25%. Investors are watching closely to see how recent developments may shape future ...

Crispr stock jumped Monday while Intellia shares surged on promising updates for their gene-editing efforts in cholesterol ...

Investing.com -- Intellia Therapeutics Inc (NASDAQ:NTLA) stock soared 13.8% in premarket trading Monday after the gene editing company presented positive clinical data for its hereditary angioedema ...

Thinking about CRISPR Therapeutics and wondering if now is your chance to scoop up value, or if the stock is already priced in with the excitement? Let's break down what the numbers and news say about ...

CRISPR Therapeutics AG (CRSP) ended the recent trading session at $55.16, demonstrating a -2.56% change from the preceding day's closing price. The stock trailed the S&P 500, which registered a ...

Now, London is going from taker to maker – it has the opportunity to become an originator at the frontier of innovation, as well as continuing to receive innovation from other c ...

Meanwhile, ARK sold 15,362 shares of Roku Inc (NASDAQ:ROKU) through its ARKK ETF, totaling $1,668,774. This marks a continuation of ARK’s recent trend of reducing its holdings in the streaming ...

It is a smart strategy to diversify your portfolio by investing in high-quality companies built on proven technologies.